Indian Pharmas Cleared Of Price-Fixing By U.K. Court
This article was originally published in PharmAsia News
Executive Summary
A U.K. court denied price-collusion allegations against five pharmaceuticals, including at least two with Indian ties. Goldshield, founded by India's Ajit Patel, and Ranbaxy U.K. were among firms that had been under investigation on price-fixing allegations for more than six years by the Serious Fraud Office. A U.K. court cleared the companies of a conspiracy allegation brought by the National Health Service concerning the prices of antibiotics and other common drugs. The court decided the allegations involved actions that allegedly occurred before the U.K. adopted a law making price-fixing an offense. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.